

COMMENTARY

Highlighting the need for better care planning in young-onset dementia

Commentary on “Comparing survival and mortality in patients with late-onset and young-onset vascular dementia” by Yoo *et al.*

Joanne Rodda¹ and Janet Carter²

¹Medway CMHSOP, Britton House, Britton Farm Gillingham, Kent ME7 1AL, UK

²Department of Psychiatry, Faculty of Brain Sciences, Maple House, UCL London W1T 7NF UK

Email: j.carter@ucl.ac.uk

Young-onset dementia (YOD) is widely accepted as dementia with onset below the age of 65 years (van de Veen *et al.*, 2022). People living with YOD have distinctive and wide-ranging needs due to age, life stage, and the range of rare diagnoses. YOD is associated with delays in diagnosis, high socio-economic impact (Kandiah *et al.*, 2016), increased carer burden (Lim *et al.*, 2018), and increased rate of neuropsychiatric symptoms (Van Vliet *et al.*, 2013a) compared to late-onset (LO) dementia. The numerical dominance of LO dementia means that service provision for YOD remains highly variable, with poorly defined care pathways, lack of specialist services, and limited access to targeted care planning and age-specific interventions that promote continuing capability and well-being (Carter *et al.*, 2018).

In order to inform the development of services and to provide clear information to young people and their families living with dementia, more data regarding the presentation and course of YOD are needed.

Currently, understanding of important areas of YOD is lacking, with the variability in reports of time to diagnosis being a prime example of this. A key study found that diagnosis in YOD takes twice as long as in LO dementia (4.4 vs 2.8 years) (Van Vliet *et al.*, 2013b). Draper *et al.* (2016) found a similarly prolonged journey to diagnosis, with a mean time to final diagnosis of specific dementia subtype of 4.7 years. Factors that may influence time to diagnosis include access to specialist services. In *International Psychogeriatrics*, a 2022 study by Loi *et al.* (2022) demonstrated that access to a specialist multidisciplinary YOD service may reduce time to diagnosis by 12 months. Stamou *et al.* (2021) reported that individuals diagnosed in a specialist YOD service compared to other settings are more likely to receive

support within the first 6 weeks and receive ongoing care in the service where they were diagnosed. Specialist services also performed better than other types of service on quality indicators, including providing care plans and key workers. These findings underscore the improved continuity, quality, and satisfaction that can be delivered by specialist services.

In order to improve understanding of YOD and in order to plan appropriate specialist services that meet need, better insight into survival time and comorbid influences is necessary.

Consensus in the literature regarding survival varies. For example, a 6-year cohort follow-up study in individuals with YOD in the Netherlands (Gerritsen *et al.*, 2019) identified that later age of onset of dementia was associated with reduced survival time after symptom onset and diagnosis. Individuals with young-onset Alzheimer's disease had statistically significant shorter survival times compared to those with vascular dementia (VaD) (median 8.6 and 14.6, respectively). However, the authors were not able to account for the uncertainties derived from self-report about symptom onset, nor the possibility that people with YOD were overrepresented in the 21% attrition due to their prolonged survival. Furthermore, a cohort control study of individuals diagnosed in a memory service using a death registry identified no difference in survival from diagnosis in YO versus LO dementia (Rhodius-Meester *et al.*, 2019). A recent analysis of national dementia datasets in England demonstrated that 55.1% of those currently living with dementia aged between 65 and 69 years were diagnosed under the age of 65 years (young onset). Of this age group, half have lived with dementia for 3 years or less, 25% for more than 5 years, and 5% in excess of 12 years (Carter *et al.*, 2022).

Prior to the study by Yoo *et al.* (2023) in *International Psychogeriatrics*, no specific data were available regarding the impact of age of onset on survival specifically in VaD. This represents an important advance since VaD is a potential target for primary prevention, particularly in “older onset” YOD (ages 45–65 years) where causes of dementia are less likely to be genetic.

In their retrospective case note review, Yoo *et al.* investigated survival in people with young-onset VaD (YO-VaD, $n = 43$) compared to those with LO-VaD ($n = 37$) and predictors of mortality. The study reported that median survival for LO-VaD was 6.1 years and for YO-VaD 12.8 years. The only significant predictor of mortality was increasing age, with no effect found for the number of vascular risk factors, smoking status, hypertension, or Hachinski score (Hachinski *et al.*, 2012). Of note, VaD conferred a high risk of mortality compared to the general population, approximately 3× for LO-VaD and 6× for YO-VaD. With each year of advancing age, mortality risk increased by approximately 6%.

The key finding from this study is that younger people living with VaD have shorter life expectancy than age peers but live for longer with dementia than people with LO VaD. While the study presents new data in the field of survival and mortality in YO VaD, some of the findings conflict with those from a detailed meta-analysis where cardiovascular risk factors and cardiovascular disease were associated with increased mortality in individuals with dementia (van Vorst *et al.*, 2016). The authors recognise the limitations of the study including the specialist (tertiary neuropsychiatry inpatient) sample, retrospective design, use of neuroimaging reports rather than image analysis, and lack of information on severity of cerebrovascular disease or pathological diagnosis.

Perhaps the most significant impact from new studies on survival in for individuals, families, and those working in the field is the emerging data about length of time lived after diagnosis. As Yoo *et al.* acknowledge, such contemporaneous information can help clinicians answer questions such as How long do I have? It also highlights that a diagnosis may present a relatively long time frame to address changing needs, impact on carers and wider family and opportunities for holistic advanced care planning (Van Rickstal *et al.*, 2023). All have implications for provision of appropriate service models in this cohort.

Questions remain about the relationship between vascular risk factors and vascular disease on survival

and mortality in YOD. In the Yoo *et al.* study, no association was found between either Hachinski score or cardiovascular risk factors and survival in either YO or LO VaD.

Current efforts in the field to reduce risk of dementia is focused primarily on modifiable environmental risk factors and vascular risk factors such as hyperlipidaemias, obesity, smoking, diabetes, and hypertension in midlife. Understanding risk factors for YOD, for example, how or if they differ from those for LO disease and how they may vary with dementia subtype is important in informing efforts for prevention in nongenetic disease. Limited high-quality evidence from prospective longitudinal studies is available, but collective evidence is accruing about “critical windows” in early and adult life that differentially affect risk of neurodegenerative disease and a dose–response relationship for all-cause YOD depending on number and interaction with other exposures, across the life span (Cations *et al.*, 2019). Recent commentary published in *International Psychogeriatrics* (Pini and Wennberg, 2022), for example, referenced a longitudinal follow-up of a birth cohort (Krishna *et al.*, 2022) which found that greater size at birth was associated with better cognitive function in later life, and this was partially mediated by childhood growth and environment. Of note, there was no evidence that midlife cardiometabolic factors mediated this association.

YOD is a clinically heterogeneous condition without the confounding effects of frailty. Risk factors applicable to older groups may or may not be generalizable. The data presented by Yoo *et al.* provide new evidence regarding survival and risk factors in a specific clinical cohort. The next, not insignificant, challenge remains extending such knowledge in epidemiological studies that consider risk over the life course of individuals and the differential effect of dementia subtype in well-defined cohorts without genetic risk.

Conflict of interest

None.

Description of authors’ roles

The authors, Joanne Rodda and Janet Carter, equally contributed to the manuscript, revised, read, and approved the submitted version.

References

- Carter, J. E., Oyeboode, J. R. and Koopmans, R. T. C. M.** (2018). Young-onset dementia and the need for specialist care. *Aging Mental Health*, 22, 468–473.
- Carter, J., Jackson, M., Gleissner, Z. and Verne, J.** (2022). Prevalence of all cause young onset dementia and time lived with dementia: analysis of primary care health records. *Journal of Dementia Care*, 30, 1–5.
- Cations, M., Withall, A. and Draper, B.** (2019). Modifiable risk factors for young onset dementia. *Current Opinion in Psychiatry*, 32, 138–143.
- Draper, B. et al.** (2016). Time to diagnosis in young-onset dementia and its determinants: the INSPIRED study. *International Journal of Geriatric Psychiatry*, 31, 1217–1224, 2016–11.
- Gerritsen, A. et al.** (2019). Survival and life-expectancy in a young-onset dementia cohort with six years of follow-up: the NeedYD-study. *International Psychogeriatrics*, 31, 1781–1789.
- Hachinski, V. C., Oveisgharan, S., Kimball Romney, A. and Shankle, W. R.** (2012). Optimising the Hachinski Ischemic Scale. *Archives of Neurology*, 69, 169–175.
- Kandiah, N. et al.** (2016). Cost related to dementia in the young. *Journal of Alzheimer's Disease*, 49, 277–285.
- Krishna, M. et al.** (2022). Size at birth, life course factors, and cognitive function in late life: findings from the MYsore study of Natal effects on Ageing and Health (MYNAH) cohort in South India. *International Psychogeriatrics*, 34, 353–366.
- Lim, L., Zhang, A., Lim, L., Silva, E., Ng, A. and Kandiah, N.** (2018). High caregiver burden in young onset dementia. *Journal of Alzheimer's Disease*, 61, 537–543.
- Loi, S. M. et al.** (2022). Time to diagnosis in younger-onset dementia and the impact of a specialist diagnostic service. *International Psychogeriatrics*, 34, 367–375.
- Pini, L. and Wennberg, A.** (2022). Critical windows into a changing world: taking a life course and cohort view of Alzheimer's disease and related dementias risk. *International Psychogeriatrics*, 34, 311–313.
- Rhodijs-Meester, H. F. M. et al.** (2019). Survival in memory clinic cohort is short, even in young-onset dementia. *Journal of Neurology, Neurosurgery & Psychiatry*, 90, 726–728.
- Stamou, V. et al.** (2021). Services for people with young onset dementia: the 'Angela' project national UK survey of service use and satisfaction. *International Journal of Geriatric Psychiatry*, 36, 411–422.
- van de Veen, D. et al.** (2022). PRECODE study group, de Vugt, M. and Koopmans, R., 2022. Provisional consensus on the nomenclature and operational definition of dementia at a young age, a Delphi study. *International Journal of Geriatric Psychiatry*, 37.
- Van Rickstal, R., De Vleminck, A., Engelborghs, S. and Van den Block, L.** (2023). Experiences with and perspectives on advance care planning in young-and late-onset dementia: a focus group study with physicians from various disciplines. *Frontiers in Aging Neuroscience*, 15, 1130642.
- Van Vliet, D., et al.** (2013). Time to diagnosis in young-onset dementia as compared with late-onset dementia. *Psychological Medicine*, 43, 423–432.
- van Vliet, D. et al.** (2013). Prevalence of neuropsychiatric symptoms in young-onset compared to late-onset Alzheimer's Disease – Part 1: Findings of the two-year longitudinal NeedYD study. *Dementia and Geriatric Cognitive Disorders*, 34, 319–327.
- Van Vorst, I. E., Koek, H. L., de Vries, R., Bots, M. and Reijtsma, J. B.** (2016). Effect of vascular risk factors and disease on mortality in individuals with dementia: a systematic review and meta-analysis. *Journal of the American Geriatrics Society*, 64, 37–46.
- Yoo, M. et al.** (2023). Comparing survival and mortality in patients with late-onset and young-onset vascular dementia. *International Psychogeriatrics*, 35, 519–527.